Moleculin Biotech Files 8-K on Financials
Ticker: MBRX · Form: 8-K · Filed: Aug 13, 2025 · CIK: 1659617
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Moleculin Biotech dropped an 8-K on Aug 13th detailing financials. Check it out.
AI Summary
Moleculin Biotech, Inc. filed an 8-K on August 13, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the date of the earliest event reported being August 13, 2025. The company is incorporated in Delaware and headquartered in Houston, Texas.
Why It Matters
This 8-K filing provides crucial updates on Moleculin Biotech's financial health and operational results, which are essential for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any immediate or significant negative developments.
Key Players & Entities
- Moleculin Biotech, Inc. (company) — Registrant
- August 13, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Houston, TX (location) — Principal executive offices
FAQ
What specific financial information is being disclosed in this 8-K filing?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported was on August 13, 2025.
What is Moleculin Biotech, Inc.'s principal executive office address?
The principal executive offices are located at 5300 Memorial Drive, Suite 950, Houston, TX 77007.
What is the Commission File Number for Moleculin Biotech, Inc.?
The Commission File Number is 001-37758.
What is the Standard Industrial Classification code for Moleculin Biotech, Inc.?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 450 words · 2 min read · ~2 pages · Grade level 9.6 · Accepted 2025-08-13 08:05:11
Filing Documents
- mbrx20250811_8k.htm (8-K) — 27KB
- ex_851330.htm (EX-99.1) — 119KB
- a01.jpg (GRAPHIC) — 10KB
- moleculinlogo.jpg (GRAPHIC) — 12KB
- 0001437749-25-026357.txt ( ) — 337KB
- mbrx-20250813.xsd (EX-101.SCH) — 3KB
- mbrx-20250813_def.xml (EX-101.DEF) — 12KB
- mbrx-20250813_lab.xml (EX-101.LAB) — 15KB
- mbrx-20250813_pre.xml (EX-101.PRE) — 12KB
- mbrx20250811_8k_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 13, 2025, Moleculin Biotech, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended June 30, 2025 and recent operational highlights. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated August 13, 2025 104 Cover page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MOLECULIN BIOTECH, INC. Date: August 13, 2025 By: /s/ Jonathan P. Foster Jonathan P. Foster Chief Financial Officer